Den europeiske union - norsk - EMA (European Medicines Agency)

zoetis belgium sa - valpesyke virus, belastning cdv bio 11/en, hjørnetann adenovirus type 2, belastning cav-2 bio 13, parvovirus type 2b, belastning cpv-2b bio 12/b, hjørnetann parainfluensa type 2-virus, belastning cpiv-2 bio 15 (alle levende svekket), leptospira interrogans serogruppe australis serovar bratislava, belastning mslb 1088, l. interrogans serogruppe icterohaemorrhagiae serovar icterohaemorrhagiae, belastning mslb 1089, l. interrogans serogruppe canicola serovar canicola, belastning mslb 1090, l. kirschneri serogruppe grippotyphosa serovar grippotyphosa, belastning mslb 1091... - live valpesyke virus + live hjørnetann adenovirus + live hjørnetann parainfluensa virus + live parvovirus + inaktivert leptospira, immunologicals for canidae - hunder - aktiv vaksinasjon av hunder fra 6 ukers alder:for å forhindre dødelighet og kliniske tegn forårsaket av valpesyke virus,for å forhindre dødelighet og kliniske tegn forårsaket av hund adenovirus type 1,for å hindre kliniske tegn og redusere viral utskillelse forårsaket av hund adenovirus type 2,for å hindre kliniske tegn, leucopoenia og viral utskillelse forårsaket av parvovirus,for å hindre kliniske tegn (nese og okulær utslipp) og redusere viral utskillelse forårsaket av hund parainfluensa virus,for å hindre kliniske tegn, infeksjon og urinutskillelse forårsaket av l. interrogans serogruppe australis serovar bratislava,for å hindre kliniske tegn og urinutskillelse og redusere infeksjon forårsaket av l. interrogans serogruppe canicola serovar canicola og l. interrogans serogruppe icterohaemorrhagiae serovar icterohaemorrhagiae og for å forhindre kliniske tegn og redusere infeksjon og urinutskillelse forårsaket av l. interrogans serogruppe grippotyphosa serovar grippotyphosa.

Den europeiske union - norsk - EMA (European Medicines Agency)

zoetis belgium sa - valpesyke virus, belastning cdv bio 11/en, hjørnetann adenovirus type 2, belastning cav-2 bio 13, parvovirus type 2b, belastning cpv-2b bio 12/b, hjørnetann parainfluensa type 2-virus, belastning cpiv-2 bio 15 (alle levende svekket), leptospira interrogans serogruppe australis serovar bratislava, belastning mslb 1088, l. interrogans serogruppe icterohaemorrhagiae serovar icterohaemorrhagiae, belastning mslb 1089, l. interrogans serogruppe canicola serovar canicola, belastning mslb 1090, l. kirschneri serogruppe grippotyphosa serovar grippotyphosa, belastning mslb 1091... - live valpesyke virus + live hjørnetann adenovirus + live parainfl.viruset + live parvovirus + inaktivert rabies + inaktivert leptospira, immunologicals for canidae - hunder - aktiv vaksinasjon av hunder fra 8-9 ukers alder:for å forhindre dødelighet og kliniske tegn forårsaket av valpesyke virus,for å forhindre dødelighet og kliniske tegn forårsaket av hund adenovirus type 1,for å hindre kliniske tegn og redusere viral utskillelse forårsaket av hund adenovirus type 2,for å hindre kliniske tegn, leucopoenia og viral utskillelse forårsaket av parvovirus,for å hindre kliniske tegn (nese og okulær utslipp) og redusere viral utskillelse forårsaket av hund parainfluensa virus,for å hindre kliniske tegn, infeksjon og urinutskillelse forårsaket av l. interrogans serogruppe australis serovar bratislava,for å hindre kliniske tegn og urinutskillelse og redusere infeksjon forårsaket av l. interrogans serogruppe canicola serovar canicola og l. interrogans serogruppe icterohaemorrhagie serovar icterohaemorrhagiae,for å hindre kliniske tegn og redusere smitte og urinutskillelse forårsaket av l. interrogans serogruppe grippotyphosa serovar grippotyphosa og for å forhindre dødelighet, kliniske tegn og infeksjon forårsaket av rabiesvirus.

Den europeiske union - norsk - EMA (European Medicines Agency)

intervet international b.v. - live attenuated canine distemper virus strain onderstepoort: 105.1 – 106.5 tcid50, live recombinant canine parvovirus strain 630a: 105.1 – 106.7 tcid50 - immunologicals for canidae - dogs (small) - for the active immunisation of puppies from 4 weeks of age onwards to prevent clinical signs and mortality of canine distemper virus infection and canine parvovirus infection and to prevent viral excretion following canine distemper virus infection and following canine parvovirus infection.

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - katter - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. immunitetstrinn har blitt vist en uke etter primær vaksinasjonskurs for rhinotrakeitt, calicivirus, chlamydophila felis og panleukopeni-komponenter. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - katter - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Den europeiske union - norsk - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vaksiner - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 og 4. bruk av dengvaxia skal være i samsvar med offisielle anbefalinger.

Den europeiske union - norsk - EMA (European Medicines Agency)

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - dengue - vaksiner - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals for felidae, - katter - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals for felidae, - katter - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - katter - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.